NAV Growth
Growth of each fund's NAV over the selected period, rebased to 0%
-
-
-
1M
3M
6M
1Y
3Y
5Y
Fund Details
| Fund Details | Aditya Birla SL Pharma & Healthcare Fund - Dir (G) | Bandhan Healthcare Fund - Direct (G) |
|---|---|---|
| Fund Type | Equity | Equity |
| Risk | Very High | Very High |
| Min SIP Amount | ₹10 | ₹100 |
| Min Lumpsum | ₹1,000 | ₹1,000 |
| Expense Ratio | 1.07% | 1.31% |
| NAV | ₹37.28 (23 Oct 2026) | ₹10.41 (23 Oct 2026) |
| Fund Size | ₹1,077.52 Cr | ₹326.54 Cr |
| Fund Started | 11 Jul 2019 | 28 Nov 2025 |
| Lock-in Period | No lock-in | No lock-in |
| Exit Load |
Returns
| Returns | Aditya Birla SL Pharma & Healthcare Fund - Dir (G) | Bandhan Healthcare Fund - Direct (G) |
|---|---|---|
| 1M | -9.32% | -10.01% |
| 3M | -6.10% | -4.63% |
| 6M | 7.10% | 6.61% |
| 1Y | 7.96% | — |
| 3Y | 19.06% | — |
| 5Y | 13.38% | — |
| Since Inception | 19.70% |
Risk Ratios
Trailing risk-adjusted performance measures
| Risk Ratio | Aditya Birla SL Pharma & Healthcare Fund - Dir (G) | Bandhan Healthcare Fund - Direct (G) |
|---|---|---|
| Alpha | 15.19 | 26.05 |
| Beta | 0.65 | 0.72 |
| Sharpe | 0.93 | 0.52 |
| Standard Deviation | 4.50 | 4.97 |
Holding Analysis
| Holding Analysis | Aditya Birla SL Pharma & Healthcare Fund - Dir (G) | Bandhan Healthcare Fund - Direct (G) |
|---|---|---|
| Top 5 Holdings | 35.22% | 33.66% |
| Top 10 Holdings | 54.43% | 54.33% |
| Portfolio Turnover | 0.18 | 0.55 |
| Equity | 97.94% | 93.55% |
| Debt | 2.92% | 6.72% |
| Cash | — | — |
Top Holdings
Aditya Birla SL Pharma & Healthcare Fund - Dir (G)
Fund Manager
| Fund Manager | Aditya Birla SL Pharma & Healthcare Fund - Dir (G) | Bandhan Healthcare Fund - Direct (G) |
|---|---|---|
| Name | — |
About Fund
| About | Aditya Birla SL Pharma & Healthcare Fund - Dir (G) | Bandhan Healthcare Fund - Direct (G) |
|---|---|---|
| AMC | Aditya Birla Sun Life Mutual Fund | Bandhan Mutual Fund |
| Scheme Category | Sectoral Fund | Sectoral Fund |
| Benchmark | BSE Healthcare TRI | BSE Healthcare TRI |
| Launch Date | 20 Jun 2019 | 10 Nov 2025 |
